CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
CureVac's focus is on developing vaccines for infectious diseases and drugs to treat for cancer and rare diseases.
Curevac was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Muelbe, Gunther Jung and Hans-Georg Rammensee. The company is based in Tübingen, Baden-Württemberg, Germany.
CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. It technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations, and the International AIDS Vaccine Initiative.
CureVac is backed by Bill & Melinda Gates Foundation, Qatar Investment Authority, German Kreditanstalt für Wiederaufbau (KfW), GlaxoSmithKline, European Investment Bank, Baillie Gifford & Co, Hopp BioTech holding and others. The company has raised a total of $1.1B in funding to date. CureVac was valued at $1.65B (€1.40B) after it had raised a new capital in 2017.
CureVac began public trading on the NASDAQ exchange on Aug 14, 2020, under the ticker symbol, CVAC, raising US$213 million in its initial public offering. The IPO gives CureVac a valuation of about $2.8B.